Loading
Dexcom Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Nov 2025.
Dexcom Inc: what insiders have been doing
Every trade that managers of Dexcom Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in San Diego, United States. It was founded in 1999. 25 insiders have disclosed 77 filings since 18 October 2025.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €748k) and 23 sales (8 insiders, €7.9M). No amount is published for 3 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. At €1.8M, the sale published on 21 July 2026 by Sayer Kevin R is the largest of the period (0.0061% of market cap). On the buying side, the filings list 1 senior executive among the declarants.
Compared with its exchange (5,810 companies, median 19 filings), a count of 77 filings is above the norm. Over the whole record (from 2016), the tally stands at 1 purchase and 210 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 4.66 bn USD and net income of 836.3 m USD.
The last insider purchase was made public on 10 November 2025, 342 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
413
Thresholds
n/a
Buy Volume
€747,703
1 ops. · all time
Sell Volume
€99M
210 ops. · all time
Who traded when
BuySaleMichael Jon Brown11 sales
Sadie Stern9 sales
Foletta Mark G7 sales
Heller Bridgette P6 sales
Kevin R. Sayer6 sales
Jereme M. Sylvain5 sales
+5 other insiders
Since the insiders bought
- +20.7%Entry US$58.13 · Close at T+90 US$70.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Dexcom Inc Strong Buy (bullish), based on 26 analysts. Average price target: US$96.46.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,335 of 24,148 companies
61.4
score / 100
Value41
Quality82
FCF yld3.4%
Earn yld2.7%
EV/EBITDA24.2x
ROE38%
Gross mgn60%
Net mgn18%
Debt/EBITDA1.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$83.47
Analyst consensus
26 analystsStrong buy
US$79.00Target US$96.46(+16%)US$115.00
Income statement
RevenueUS$4.7B
Gross profitUS$2.8B60% margin
EBITDAUS$1.4B29% margin
Net incomeUS$836.3M20.1% margin
Valuation
PER (trailing)33.8x
PER (forward)26.7x
P/Book12.0x
Beta1.48
Balance sheet & cash
Market capUS$31.5B
Total debtUS$1.4B
Free Cash FlowUS$1.1B
Debt / Equity53%
Profitability & ownership
ROE38.5%
ROA10.3%
% insiders0.3%
% institutions106.5%
Last declaration on 15 October 2026
Declarations413 total
1,700 shares@ US$85.48CommonSEC144:0001950047-26-010231
2,565 shares@ US$86.150.0007% mcap2.9% of flowCommon StockSEC:0001093557-26-000181:0
2,565 shares@ US$86.150.014% mcap50.0% of flowCommonSEC144:0001950047-26-009837
1,700 shares@ US$84.040.0004% mcap2.5% of flowCommon StockSEC:0001093557-26-000178:0
6,539 shares@ US$84.040.0016% mcap15.8% of flowCommon StockSEC144:0001959173-26-006959
1,700 shares@ US$84.040.0087% mcap25.8% of flowCommonSEC144:0001950047-26-009460
1,550 shares@ US$84.020.0004% mcap3.7% of flowCommon StockSEC144:0001959173-26-006910
3,638 shares@ US$83.270.0009% mcap3.7% of flowCommon StockSEC:0001093557-26-000173:0
3,638 shares@ US$83.270.018% mcap100.0% of flowCommonSEC144:0001950047-26-009273
5,841 shares0Common StockSEC:0001093557-26-000171:0
2,565 shares@ US$88.370.0007% mcap3.0% of flowCommon StockSEC:0001093557-26-000161:0
2,565 shares@ US$88.370.014% mcap100.0% of flowCommonSEC144:0001950047-26-008745
1,451 shares@ US$92.340.0004% mcap2.3% of flowCommon StockSEC:0001093557-26-000157:0
1,451 shares@ US$92.340.0004% mcap1.8% of flowCommon StockSEC:0001093557-26-000156:0
1,451 shares@ US$92.340.0004% mcap1.6% of flowCommon StockSEC:0001093557-26-000158:0
1,451 shares@ US$92.340.0004% mcap0.5% of flowCommon StockSEC:0001093557-26-000159:0
7,351 shares@ US$90.78110.0020% mcap1.7% of flowCommon StockSEC:0001093557-26-000151:1
19,308 shares@ US$89.7060.0051% mcap4.4% of flowCommon StockSEC:0001093557-26-000151:0
97 shares@ US$91.410.0000% mcap0.0% of flowCommon StockSEC:0001093557-26-000151:2
26,756 shares@ US$90.00750.14% mcap37.3% of flowCommonSEC144:0001950047-26-008475
1,700 shares@ US$91.930.0005% mcap2.7% of flowCommon StockSEC:0001093557-26-000149:0
1,700 shares@ US$91.930.0095% mcap28.2% of flowCommonSEC144:0001950047-26-008128
1,075 shares0Common StockSEC:0001093557-26-000147:0
1,012 shares@ US$88.290.0003% mcap13.8% of flowCommonSEC144:0001959173-26-005920
2,000 shares@ US$85.320.0005% mcap12.4% of flowCommonSEC144:0001969223-26-000825
25 of 413 declarations
About Dexcom Inc
DexCom, Inc. is a leading medical technology company focused on continuous glucose monitoring (CGM) for people living with diabetes. The company is listed in the United States on the NASDAQ market under the ticker DXCM. Founded in 1999, DexCom has built a strong position in glucose biosensing and has become one of the best-known names in CGM. Its headquarters are in California, United States, and its business model centers on the design, manufacturing, and commercialization of glucose sensors, transmitters, and companion software that deliver real-time glucose data and digital health integration. ([investors.dexcom.com](https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx?utm_source=openai))
Commercially, DexCom derives most of its revenue from CGM systems sold to diabetes patients, with the Dexcom G7 serving as its flagship offering. The company addresses both insulin-treated patients and a broader, expanding user base as CGM adoption increases. DexCom’s competitive standing is supported by its brand recognition, measurement accuracy, and deep integration with connected-care ecosystems. That combination has helped it remain one of the most visible and influential players in the diabetes technology segment, competing with other established leaders in glucose monitoring and automated diabetes care. ([investors.dexcom.com](https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx?utm_source=openai))
Read moreShow less
From a geographic perspective, DexCom has an international footprint. It sells in the United States and continues expanding outside the U.S., supported by a growing commercial and regulatory infrastructure. For investors in French-speaking markets, that international diversification is important because it reduces reliance on a single market and supports the company’s long-term growth profile. DexCom has also emphasized broader product access through pharmacy channels and specialized distribution routes, which can improve adoption and convenience for patients. ([investors.dexcom.com](https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx?utm_source=openai))
Recent developments are important to the investment case. DexCom released preliminary full-year 2025 results and initial 2026 guidance, followed by first-quarter 2026 financial results. The company also announced governance enhancements ahead of its 2026 Investor Day and a leadership transition with Jake Leach becoming President and Chief Executive Officer. On the product side, the Dexcom G7 15 Day CGM System began shipping to pharmacies in early January 2026, extending the company’s product range and commercial reach. Overall, DexCom remains a growth-oriented name in Health & Pharma, tied to CGM adoption, product innovation, and competition in the U.S. NASDAQ-listed medical device market. ([investors.dexcom.com](https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
